[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study.

Purpose: The use of [177Lu]Lu-PSMA-617 radioligand therapy has become increasingly recognized as a viable therapeutic approach for patients in the advanced stages of metastatic castration-resistant prostate cancer (mCRPC). However, there is limited data regarding its effectiveness and safety in earl...

Full description

Bibliographic Details

Published in:	European Journal of Nuclear Medicine & Molecular Imaging Vol. 51; no. 8; pp. 2495 - 2504
Main Authors:	Satapathy, Swayamjeet, Yadav, Madhav Prasad, Ballal, Sanjana, Sahoo, Ranjit Kumar, Bal, Chandrasekhar
Format:	Journal Article
Published:	Springer Nature Jul2024
Online Access:	View this record in EBSCOhost